Skip to content
HowShorted

XERIS PHARMACEUTICALS INC short interest in 2020

In 2020, XERIS PHARMACEUTICALS INC's disclosed short interest ran from 8.09% of shares outstanding on 15 Jan 2020 to 10.37% on 31 Dec 2020, a change of +2.28 percentage points. The year's high was 38.20% on 15 Oct 2020 and its low 3.70% on 15 Jun 2020, averaging 16.79% across 22 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 12.88 days on 31 Jan 2020. Full history: XERIS PHARMACEUTICALS INC.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021

Aggregate net short position time series for XERIS PHARMACEUTICALS INC in 2020

2020 in figures

Start of year
8.09% (15 Jan 2020)
End of year
10.37% (31 Dec 2020)
Change
+2.28 pp
High
38.20% (15 Oct 2020)
Low
3.70% (15 Jun 2020)
Average
16.79%
Highest days to cover
12.88 (31 Jan 2020)
SEC filings marked
9

Every report in 2020

XERIS PHARMACEUTICALS INC short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 20208.09%5.45
31 Jan 20207.90%12.88
14 Feb 20204.71%1.25results (8-K)
28 Feb 20205.61%2.22
13 Mar 20205.86%2.60results (8-K), 10-K filed
31 Mar 20206.39%4.20
15 Apr 20206.74%5.18
30 Apr 20205.65%3.81
15 May 20206.23%2.3610-Q filed, results (8-K)
29 May 20203.72%2.32
15 Jun 20203.70%3.69
31 Jul 202028.70%5.98
14 Aug 202032.90%3.6810-Q filed, results (8-K)
31 Aug 202035.91%3.50
15 Sep 202034.59%5.43
30 Sep 202037.87%5.47
15 Oct 202038.20%10.98
30 Oct 202031.33%12.02
13 Nov 202030.23%11.2710-Q filed, results (8-K)
30 Nov 202013.97%4.36
15 Dec 202010.77%2.96
31 Dec 202010.37%2.96

See also: XERIS PHARMACEUTICALS INC's full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.